Here’s what you need to know.
1. The company traded at $21.05 on Friday. It opened the day at $21.73.
2. Director Brian E. Farley sold 30,000 of the firm’s shares for a total of $667,800.
3. Mr. Farley owns 514,581 shares of the company at a value of $11.4 million.
4. Despite that four research analysts still gave the firm a buy rating. Zacks Investment recently downgraded Entellus from a buy rating to a hold rating.
More spine/ortho news:
25 Mazor systems purchased in Q3, Medtronic accounts for 15
St. Jude Medical receives FDA approval, announces 1st implant of Infinity DBS system: 5 observations
Medicrea’s 2016 Q3 sales hit €6.8M — 6 report highlights
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 18–20 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
